TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30877271
Drug: Citalopram infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram infusion in healthy controls
Study: 30877271
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion in MDD patients
Study: 30877271
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion in healthy controls
Study: 28540894
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 1 mg/kg/day for 3 months
Study: 21729686
Drug: AEG35156 (650
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEG35156 (650 mg) in combination with high-dose cytarabine and idarubicin
Study: 21729686
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine and idarubicin alone
Study: 19192840
Drug: 15% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% carbamide peroxide gel (bleaching group)
Study: 16983592
Drug: Neoadjuvant 8-week
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant 8-week dose-dense doxorubicin plus docetaxel
Study: 12734908
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (6.0 g/day)
Study: 11061657
Drug: Standard recommendation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard recommendation of 200 mg daily during the first 2 weeks (n = 166)
Study: 11061657
Drug: Prednisone 50
Normalized name: prednisone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 50 mg every other day during the first 2 weeks (n = 93)
Study: 11061657
Drug: Slowly escalating
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slowly escalating dose starting with 100 mg daily (n = 107)
Study: 11061657
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prednisone and slowly escalating dose (n = 103)
Study: 11061657
Drug: New approaches
Approvals — FDA: no, EMA: no, PMDA: no
Description: New approaches (including prednisone and slowly escalating dose)
Study: 9077371
Drug: IGF‐I [8
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐I [8 micrograms kg‐1 h‐1] by continuous subcutaneous infusion
Study: 9077371
Drug: GH (6
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH (6 U. twice daily s.c.) for 5 days
Study: 26290867
Drug: LC n‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LC n‐3 PUFAs (2.52 g/day)
Study: 18555827
Drug: Full-dose almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose almonds (73 +/- 3 g/d)
Study: 18424600
Drug: Half-dose almonds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose almonds plus half-dose muffins
Study: 8780944
Drug: Thymostimulin (TP1)
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymostimulin (TP1) at dosages of 0.5 mg/kg, 1.0 mg/kg, and 2.0 mg/kg body weight
Study: 1623900
Drug: dexfenfluramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexfenfluramine (30 mg daily)
Study: 6597721
Drug: Indometacin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (3 X 50 mg daily)
Study: 6597721
Drug: Carprofen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carprofen (2 X 150 mg daily)
Study: 6597721
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 X daily)
Study: 12470198
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (400 mg/day for 6 weeks)
Study: 2782269
Drug: Propranolol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol + Nifedipine (10 or 20 mg every 8 hours)
Study: 2782269
Drug: Propranolol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol + Diltiazem (60 or 120 mg every 8 hours)
Study: 23319447
Drug: High-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat diet (15.4 g of fat)
Study: 23319447
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet (4.0 g of fat)
Study: 21422304
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment to the left temporoparietal junction for 2 weeks
Study: 21422304
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of active rTMS vs sham treatment
Study: 8133561
Drug: Rice-based ORS
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice-based ORS (50 g/l)
Study: 3304028
Drug: Oral clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral clonidine (400 micrograms/day) for twelve weeks
Study: 27736760
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg intravenous (i.v.) omadacycline
Study: 27736760
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral tablet formulation of omadacycline
Study: 27736760
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg oral solution of omadacycline
Study: 18701647
Drug: CMRI vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMRI vaccine (0.3 to 60 microg followed by a booster dose of 30 microg)
Study: 18701647
Drug: CMRI vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMRI vaccine (priming doses)
Study: 18701647
Drug: CMRI vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMRI vaccine (after booster dose)
Study: 16081857
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin daily (n=17)
Study: 12160502
Drug: Intrathecal narcotics
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal narcotics (morphine and fentanyl)
Study: 12160502
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (continuous infusion of bupivacaine and fentanyl)
Study: 10432467
Drug: Active transdermal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transdermal nicotine patch (22 mg/day)
Study: 10432467
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal nicotine patch
Study: 10432467
Drug: Both active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both active and placebo patches
Study: 7239899
Drug: hand-warming treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hand-warming treatment
Study: 7239899
Drug: hand-cooling treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hand-cooling treatment
Study: 24548627
Drug: Anti-TNF-α antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-TNF-α antibodies (monoclonal and polyclonal)
Study: 24548627
Drug: Polyclonal antibodies
Normalized name: Anti-SARS-CoV-2 Polyclonal Antibodies SAB-185
DrugBank: SAB-185 (DB16491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyclonal antibodies or receptor blockers
Study: 24548627
Drug: Anti-TNF-α therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-α therapy in patients with high levels of IL-6 (> 1000 pg/ml)
Study: 24548627
Drug: Anti-TNF-α therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-α therapy in patients with shock
Study: 12893845
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine (0.4 mg/kg)
Study: 6356318
Drug: sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate (1 g tds 2 h after each meal and 1 g nocte)
Study: 6356318
Drug: cimetidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine (200 mg tds and 400 mg nocte)
Study: 22198338
Drug: Intravenous topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous topotecan 0.5mg/m(2) and cisplatin 30 mg/m(2) given weekly for 6 weeks with pelvic radiation
Study: 22198338
Drug: Intravenous topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous topotecan 0.5mg/m(2) and cisplatin 40 mg/m(2) given weekly for 6 weeks with pelvic radiation
Study: 22198338
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin 30 mg/m(2) in combination with topotecan 0.5mg/m(2) and pelvic radiation
Study: 19443125
Drug: Framycetin 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Framycetin 1% cream (Soframycin)
Study: 17394651
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CRP testing and communication skills training
Study: 7811016
Drug: Vancomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (1 g twice daily)
Study: 2187344
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution amnioinfusion
Study: 21411800
Drug: Placebo loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo loading dose followed by conivaptan continuous i.v. infusion using the ampul formulation (regimen 1)
Study: 21411800
Drug: Conivaptan loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan loading dose followed by continuous i.v. infusion using the ampul formulation (regimen 2)
Study: 21411800
Drug: Placebo loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo loading dose followed by conivaptan continuous i.v. infusion using the premixed formulation (regimen 3)
Study: 21411800
Drug: Conivaptan loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conivaptan loading dose followed by continuous i.v. infusion using the premixed formulation (regimen 4)
Study: 11465987
Drug: Bolus-Continuous (BC-)
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus-Continuous (BC-) group (3 mg base rate/h, 1 mg bolus, 20 min lock out)
Study: 11465987
Drug: Bolus (B-)
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus (B-) group (no base rate, 1 mg bolus, 10 min lock out)
Study: 9596316
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (500 microg) before suctioning
Study: 29757375
Drug: Tablet-based consent
Normalized name: amlodipine / celecoxib Oral Tablet [Consensi]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based consent process
Study: 28043176
Drug: Control (directly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (directly observed treatment with adherence counseling alone)
Study: 22031267
Drug: Myo-inositol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myo-inositol (0.6 g in soft gel capsule or 2 g in powder)
Study: 18452885
Drug: Ivermectin 0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 0.1, 0.2, 0.2, and 0.2 mg/kg
Study: 18452885
Drug: Albendazole 6.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 6.7 mg/kg
Study: 17254459
Drug: BTX‐A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTX‐A injection guided by electric stimulation
Study: 31300331
Drug: Four RTS,S/AS01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four RTS,S/AS01 doses (four‐dose group)
Study: 31300331
Drug: Three RTS,S/AS01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three RTS,S/AS01 doses (three‐dose group)
Study: 31300331
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (four comparator doses)
Study: 24002495
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg selenized yeast daily for 48 months)
Study: 24002495
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 48 months)
Study: 21148043
Drug: Tasocitinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasocitinib (100 mg)
Study: 17352966
Drug: Acupressure using
Normalized name: ACUPRESSURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure using wristbands (Sea-Band) for 5 days post-chemotherapy
Study: 10097483
Drug: School and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: School and home-based drug prevention program
Study: 31126960
Drug: Chemotherapy (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Arm C)
Study: 23740211
Drug: Topical spray
Normalized name: Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical spray (MedSpray™ tinea pedis 1% w/w)
Study: 23740211
Drug: Topical solution
Normalized name: Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution (Lamisil® Once 1% w/w)
Study: 21041163
Drug: Colesevelam hydrochloride
Normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam hydrochloride (3.75 g)
Study: 16898431
Drug: OASIS Mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: OASIS Mouth Moisturizing Spray
Study: 15037411
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg; n = 18)
Study: 15037411
Drug: Continuous conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous conjugated estrogens (0.625 mg) combined with medroxyprogesterone acetate (5 mg; n = 19)
Study: 9387952
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine 20 mg
Study: 9387952
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine 40 mg
Study: 8133853
Drug: Intravenous immune
Normalized name: Intravenous immune globulin (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immune globulin (900 mg/kg for 501-1000 g; 700 mg/kg for 1001-1500 g), repeated every 14 days until certain criteria were met
Study: 8133853
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo infusions during phase 1, none during phase 2)
Study: 2683557
Drug: Nimodipine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (40 mg t.i.d. for 28 days)
Study: 27175447
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule daily for 12 weeks
Study: 29540864
Drug: Extended-release guanfacine
Normalized name: guanfacine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release guanfacine (GEXR)
Study: 26778524
Drug: Atorvastatin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 60 mg (AT 60)
Study: 26778524
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg (AT 20)
Study: 26778524
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (AT 60 mg and AT 20 mg)
Study: 23158914
Drug: Serum total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum total bilirubin (TBil) levels stratified into three groups: lower-level group (TBil ≤ 12.8 mmol/L), moderate-level group (TBil > 12.8 ∼ 18.2 mmol/L), higher-level group (TBil > 18.2 mmol/L)
Study: 16205916
Drug: Pregabalin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (150 mg t.i.d.)
Study: 16205916
Drug: Alprazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1 mg t.i.d.)
Study: 10629018
Drug: Itraconazole cyclodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole cyclodextrin solution
Study: 6395273
Drug: Cefonicid (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (1.0 g every 24 hr)
Study: 6395273
Drug: Cefamandole (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (1.0 g iv every 6 hr)
Study: 30128710
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (n=284)
Study: 30128710
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (n=286)
Study: 26615509
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of meloxicam
Study: 26615509
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of diclofenac
Study: 24216088
Drug: L-dopa with
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa with benserazide
Study: 22348456
Drug: Plant-extractive compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant-extractive compound
Study: 20662070
Drug: AZD5672 (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5672 (20, 50, 100, or 150 mg orally, once daily)
Study: 20662070
Drug: Etanercept (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (50 mg subcutaneously, once weekly)
Study: 15770222
Drug: Oligofructose (OFS)
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose (OFS) 16 g/day for 8 weeks
Study: 10395619
Drug: Oligofructose (Raftilose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose (Raftilose P95) 2 g three times daily for 4 weeks
Study: 10395619
Drug: Sucrose 1
Normalized name: Sucrose 1-fructosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose 1 g three times daily for 4 weeks (Control)
Study: 7671182
Drug: Diltiazem (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (calcium blocker)
Study: 7671182
Drug: No calcium
Normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No calcium blocker (control)
Study: 2019378
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of single-agent cefotaxime, 2 g IV every 8 hours
Study: 2019378
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of single-agent cefotaxime, 2 g IV every 8 hours
Study: 7082501
Drug: Histamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine infusion with cimetidine
Study: 30106876
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment with a 1-kg gain in body weight
Study: 30106876
Drug: Clozapine treatment
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine treatment with a 1-point increase in percentage of body fat
Study: 23343614
Drug: Doxazosin 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 0.03 mg/kg/d once daily before bed (group 2)
Study: 23343614
Drug: Ibuprofen 20
Normalized name: ibuprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 20 mg/kg/d divided into 2 doses for pain control (group 1)
Study: 1603535
Drug: Subconjunctival 5-fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival 5-fluorouracil (5-FU) injections, 4 to 6 injections over 10 days postoperatively.
Study: 1603535
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with 5-fluorouracil (5-FU).
Study: 24237113
Drug: Brief Symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Symptom Inventory (BSI) administered at 30, 90, and 180 days postinjury
Study: 23009189
Drug: Multi-modal exercise
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-modal exercise program (twice weekly, 60 minute classes for 16 weeks)
Study: 18986412
Drug: Nesiritide administration
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nesiritide administration
Study: 15121562
Drug: Soy-based food
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-based food supplement (n = 9) for 5 consecutive evenings
Study: 15121562
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (n = 19) for 5 consecutive evenings
Study: 11509866
Drug: co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-administration of GH and prednisolone
Study: 11509866
Drug: oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral prednisolone 50 mg/day
Study: 2824861
Drug: Adjuvant medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant medroxyprogesterone acetate (500 mg, 3 times a week for 1 year)
Study: 30138013
Drug: CBT or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT or COMB treatment
Study: 30138013
Drug: Treatment responders
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment responders and remitters
Study: 26349936
Drug: High NaCl
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High NaCl diet (32 g/d) supplemented with 90 mmol KHCO3/day for 10 days
Study: 26349936
Drug: High NaCl
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High NaCl diet (31 g/day)
Study: 26349936
Drug: Low NaCl
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low NaCl diet (3 g/day) with acidified diet
Study: 22782948
Drug: pegIFN-α2a/ribavirin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegIFN-α2a/ribavirin therapy
Study: 17924894
Drug: Midazolam (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (up to 5 mg)
Study: 9450712
Drug: Paroxetine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine, 20 to 30 mg/d
Study: 9450712
Drug: Nortriptyline, targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline, targeted to a therapeutic plasma level of 190 to 570 nmol/L (50‐150 ng/mL)
Study: 25713485
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus metronidazole in combination with scaling and root planning (SRP)
Study: 23410871
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg before emergency PCI, followed by atorvastatin 40 mg for 4 weeks and atorvastatin 20 mg for 20 weeks (Group A)